cyrilzakka/clinical-trials huggingface dataset:
Innovative Strategy to Offer Online Test and Treat for Thai MSM/TG

This study will ask Thai MSM and transgender women (TG) participants to self-select to participate in one of the 3 different study groups which provide various degrees of integrated online interventions and offline interventions for the Recruit-Test-Treat-Retain for HIV prevention and care among 3 groups (A, B1 and B2). All participants will be followed up either offline or online for 12 months. HIV-negative participants will be scheduled for repeat HTC at months 6 and 12. HIV-positive participants will be scheduled either offline or online to review their treatment history at months 6 and 12. HIV-negative participants in Group B1 and B2 can choose again at months 6 and 12 to switch from the online to offline, and vice versa, at the HIV testing/post-test counseling step and the referral to HIV treatment step


Eligibility Criteria:
Inclusion Criteria:

1. Thai national
2. Age \>18 years
3. Men or transgender women who have at least 1 unprotected anal sex with men within the past 6 months
4. Live in the Bangkok Metropolitan Region (Bangkok, Pathumthani, Samutprakarn, Samutsakorn, Nakornpathom and Nonthaburi) or Pattaya
5. Not known to be HIV-positive, i.e., never tested for HIV or previous HIV test(s) negative
6. Willing to participate in the study for 12 months.
7. Provide verbal informed consent

Exclusion Criteria:

1. Known HIV-positive serostatus
Inclinometer Reliability in Seated Shoulder Position Sense Assessment

Inclinometer Assessment of Seated Shoulder Position Sense: Intra- and Inter-Rater Reliability and Validity


Eligibility Criteria:
Inclusion Criteria:

* Healthy participants aged 18-60 with no current or past shoulder injury, trauma, or pain.

Exclusion Criteria:

* Pain in the upper extremity or neck
* Limited range of motion in the upper extremity joints
* Any history of upper extremity, cervical, or cranial injury
* Regular involvement in a sport or occupation that requires frequent overhead shoulder movements
* Performing strenuous exercise within 24 hours prior to the assessment
* Consumption of alcohol and/or illicit substances within 24 hours prior to the assessment
Effects of Oxymizer Pendant Cannula Versus Conventional Nasal Cannula During Endurance Shuttle Walk Tests in Hypoxemic Patients With Idiopathic Pulmonary Fibrosis

Aim of this study is to investigate the effects of an Oxymizer pendant nasal cannula in hypoxemic patients with idiopathic pulmonary fibrosis during walking.

Patients will be recruited during an inpatient pulmonary rehabilitation program. They will perform three shuttle walk tests on three consecutive days (see below). While performing those tests, the patient's prescribed oxygen flow rate is applicated either through the conventional nasal cannula (CNC) or the Oxymizer.On the first day, patients perform an incremental shuttle walk test to determine maximum walking speed using a conventional nasal cannula.

On two consecutive days, patients will perform two endurance shuttle walk tests at 85% of the maximum incremental shuttle walk test speed. Supplemental oxygen will be provided via nasal cannula at the prescribed oxygen flow rate. Patients will be randomly assigned to perform one test with the Oxymizer and the other one with a conventional nasal cannula.

Eligibility Criteria:
Inclusion Criteria:

* firmed diagnosis of idiopathic pulmonary fibrosis
* indication for supplemental oxygen therapy during exercise
* referred to an inpatient rehabilitation program at the Schön Klinik Berchtesgadener Land

Exclusion Criteria:

* cardiovascular diseases that influence the patient's physical performance
* orthopedic comorbidities that prevent the patient from performing an incremental or endurance shuttle walk test
* carbon dioxide pressure above 45 mmHg at rest and ambient air
Changing Lifestyle in Children

A lifestyle intervention aimed at improving exercise levels in primary school children.


Eligibility Criteria:
Inclusion Criteria

* Children 9-11 yrs

Exclusion Criteria:

* Children \<9 yrs and \>12 yrs
Panretinal Photocoagulation for Diabetic Retinopathy With PASCAL Laser

This study will investigate the clinical efficacy and safety of the PASCAL laser (PAttern SCAn Laser) for diabetic retinopathy. Patients with proliferative or severe nonproliferative retinopathy will be treated with panretinal photocoagulation utilizing different treatment strategies. The investigators believe that using "lower" laser parameters, the clinical response may be equivalent with less adverse effects.


Eligibility Criteria:
Inclusion Criteria:

* proliferative or severe nonproliferative diabetic retinopathy (type 1 or type 2)
* best corrected visual acuity of 20/50 or better
* capability to read and follow instructions
* capability to sign the consignment term

Exclusion Criteria:

* best corrected visual acuity worse than 20/50
* significant macular edema responsible for visual acuity lower than 20/50
* media opacities (includes vitreous hemorrhage in the visual axis, but not a reabsorbing inferior vitreous hemorrhage)
* previous laser treatment (PRP, focal or macular grid)
* glaucoma (confirmed or suspicious)
* other diseases of the retina and optic nerve
* previous ocular surgery in the last 6 months
* impossibility to obtain good quality images of retinography, angiography or OCT
Lowdose Nivolumab in Combination With AVD as Front Line Therapy for Classic Hodgkin's Lymphoma

This study aims to prove the efficacy and safety of low dose nivolumab (40mg as the lowest available presentation) in combination with AVD (adriamycin,vinblastine sulfate and dacarbazine) as frontline treatment for classic Hodgkin's lymphoma.

The main objective of this project is to prove the efficacy and safety of Nivolumab used as an standard dose of 40mg ( as the lowest available presentation) in combination with AVD as frontline therapy for Hodgkin's lymphoma.

Patients classification.

We will categorize patients in three groups as follows:

1. Early stages by Ann-arbor classification (I,II) with no risk factors (as stablished by NCCN's guidelines criteria).
2. Early stages by Ann.arbor classification (I,II) with risk factors ( as stablished by NCCN's guidelines criteria).
3. Advanced stages by Ann-arbor classification (III,IV).

Methodology:

* Patients will receive two initial cycles of NAVD therapy ( each with two applications in day 1 and 15) and then will be evaluated with an interim PET/CT after completing cycle 2.
* According to the PET C/T results, patients will be categorized as fast responsers (patients who achieve Deauville 1-3 classification) and low responsers ( patients who achieve Deauville 4-5).
* Fast responsers will receive following cycles without nivolumab (2 extra cycles for patients categorized as early stage with no risk factors, 4 extra cycles for patients categorized as early stages with risk factors and for advanced stages).
* Patients will receive medical evaluation at first meeting, during their treatment and after conclusion of the treatment with physical examination and laboratory tests according to medical criteria.
* Adverse effects will be recorded and managed following the guidelines for immunotherapy and chemotherapy indications.

Eligibility Criteria:
Inclusion Criteria:

* Patients with recent diagnosis of classic Hodgkin's lymphoma demonstrated by incisional or excisional biopsy of adenopathy.
* Treatment naive patients.
* Any stage
* Any functional status.

Exclusion Criteria:

* Patients with refractory or relapsed disease.
* Patients with non classical variety.
* Patients with chronic or active infections at the moment of recruiting.
* Patients younger than 16 years old.
* Pregnancy
An Implantable Microstimulator for the Chronic Treatment of Refractory Urinary Urge Incontinence

This clinical trial is being conducted to investigate the safety and effectiveness of a new device designed to treat urinary urge incontinence in those patients who have tried and failed two or more conservative therapies.


Eligibility Criteria:
Key Inclusion Criteria:

1. Age 18 years and above.
2. Diagnosed with urinary urge incontinence.
3. Have no reported history of urethral obstruction/stricture, bladder calculi or bladder tumor.
4. Have normal upper urinary tract function.
5. Be capable of giving informed consent.
6. Be capable and willing to follow all study related procedures.

Key Exclusion Criteria:

1. Have any active implantable device regardless of whether stimulation status is ON or OFF.
2. Are pregnant as confirmed by a urine pregnancy test or plan to become pregnant during the following 12 months period.
3. Less than one year post partum and/or are breast-feeding.
4. Have any passive implant that contains metal or electrically conductive materials.
5. Have conditions requiring Magnetic Resonance Imaging (MRI) evaluation.
6. Have conditions requiring diathermy procedures.
7. Have an inability to operate the bion Remote Control and bion Recharging System either by self or caregiver.
8. Have diabetes with peripheral nerve involvement or have severe uncontrolled diabetes.
9. Have history of coagulopathy or bleeding disorder.
10. Have a history of pelvic pain as primary diagnosis.
11. Have anatomical restrictions such that the study device placement is not possible.
12. Are currently participating or have participated within the past 30 days in any clinical investigation involving or impacting urinary or renal function.
13. Have a life expectancy of less than 1 year.
14. Cannot independently comprehend and complete the QoL questionnaires.
Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer

This is a Phase I/II study to evaluate the safety profile, tolerability, pharmacokinetics and pharmacodynamics following daily oral doses of 50 to 200 mg of BMS-754807 in combination with trastuzumab (Herceptin®) in subjects with advanced or metastatic Her-2-positive breast cancer. In addition, the study is expected to identify the recommended dose or dose range of BMS-754807 in combination with trastuzumab for Phase II studies and provide preliminary evidence of anti-tumor activity in Her-2-positive breast cancer subjects after trastuzumab failure


Eligibility Criteria:
For additional information on this trial, please call (910) 558-2913

Inclusion Criteria:

* Subjects with locally advanced or metastatic Her-2-positive breast cancer who have failed at least one trastuzumab containing regimen. Prior treatment with other Her-2-targeted agents (e.g. lapatinib, pertuzumab, trastuzumab DM-1 etc.) is allowed
* Histologic or cytologic diagnosis of Her-2-positive breast cancer
* ECOG status 0 - 1

Exclusion Criteria:

* Symptomatic brain metastasis
* Any condition requiring chronic use of steroids
* Any disorder with dysregulation of glucose homeostasis (history of Type 1 or 2 Diabetes Mellitus or prediabetic symptoms
* History of glucose intolerance
* Women of child-bearing potential unwilling or unable to use acceptable contraception methods
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OP-101 After Intravenous Administration in Healthy Volunteers

A clinical study to measure the effect of OP-101 after being administered intravenously in healthy volunteers.


Eligibility Criteria:
Key Inclusion Criteria:

* Body Mass Index (BMI) between 18 and 32 kg/m\^2.
* Is in general good health, based upon the results of a medical history assessment, physical examination, vital signs, laboratory profile, and 12-lead electrocardiogram (ECG), as judged by the investigator.
* Female subjects may not be pregnant, lactating, or breastfeeding.
* Subjects must have a negative urine test for drugs of abuse, cotinine, and breath alcohol test at screening and Check-in.

Key Exclusion Criteria:

* Evidence of clinically significant hematologic, renal, endocrine, pulmonary, cardiac, gastrointestinal, hepatic, psychiatric, neurologic, immunologic, allergic disease, or any other condition that, in the opinion of the Investigator, might significantly interfere with the absorption, distribution, metabolism, or excretion of study drug, or place the subject at an unacceptable risk as a participant in this study.
* History of malignancy (other than successfully treated basal cell or squamous cell skin cancer).
* History or presence of an abnormal ECG that, in the opinion of the Investigator, is clinically significant.
* Has used any product containing nicotine within 90 days prior to screening or intends to use any product containing nicotine during the course of the study.
* Has used medications that affect gastrointestinal motility or gastric emptying; such as metoclopramide, proton pump inhibitors, and H2 blockers; within 30 days prior to Day 1.
* Has used prescription or over-the-counter medication, vitamins/herbal supplements (with the exception of hormonal contraceptives) within 14 days prior to Day 1.
Treatments and Outcomes of Untreated Cerebral Cavernous Malformations in CHina.

This nationwide multicenter prospective cohort study will collect the treatment information and outcomes of the patients with previously untreated cavernous malformations (U-CMs) in China (at least 2000 patients from 20 centers). The investigators aim to determine the effect of different treatments on long-term outcomes in patients with untreated cerebral cavernous malformations.

Despite the availability of microsurgical excision and stereotactic radiosurgery for cavernoma treatment and known genetic causes of most familial forms of cavernoma, uncertainties remain about cause, diagnosis, prognosis, treatment, and care. According to the recently published CM treatment guideline, surgical and conservative treatments are both first-line therapeutic options in previously untreated CMs (U-CMs). However, given current data, neurosurgeons are still unable to counsel patients on which would be the best option. To address the absence of high level evidence to support cerebral CM treatment decisions, there is a need for a large sample size study of cerebral CM treatment with a prospective concurrent group. China has the largest population in the world and may have the most extensive and valuable clinical resources of U-CMs. But, till now, the current treatment and outcome situation of the disease in China is not well known. Thus, the investigators are conducting a nationwide multicenter prospective registry study in China to determine the effect of different treatments on long-term outcomes in patients with untreated cerebral cavernous malformations.At least 2000 patients with untreated cerebral cavernous malformation will be enrolled from 20 Grade Ⅲ A level hospitals distributed all over China. Clinical data and laboratory data are prospectively collected by electric case report form (CRF) and uploaded online by each neurosurgery center to form the prospective clinical database in First Affiliated Hospital of Fujian Medical University. This is a cohort follow-up study across a 5-year period with a 2 years interval of enrollment and 3 years follow up for each patient.

Eligibility Criteria:
Inclusion Criteria:

* Definite diagnosis of cerebral CM on the basis of brain MRI or pathologic examination;
* Patients without any surgical intervention (microsurgery, radiosurgery, or multimodality treatment) before enrolment;
* Informed consent, and willing to accept long-term follow-up.

Exclusion Criteria:

* Patients receiving emergency surgery due to acute intracranial hematoma and resultant brain hernia;
* Patients with other never system diseases, such as aneurysms, tumors or other vascular malformations except venous development anomaly;
* Patients with severe underlying disease, which affects the patient's functional status and life expectancy;
* Patients with severe mental or psychologic disease.
Swallowing Difficult Sensation After Cervical Spine Surgery

In many cases, the manometric examination is not feasible because of the pharyngeal sinusitis or pharyngeal torsion. In addition, although previous conventional manometry was used to estimate pharyngeal swallowing, the bolus flow transmission was still not evaluated, which still depended on the videofluoscopic swallowing studies. High resolution impedance manometry could help us to measure the bolus flow according to the impedance changes. However, the comparison between two approach methods of postoperative recovery of swallowing function is still inconclusive. The investigator aimed to examine the correlation between high-resolution manometric and videofluoroscopic measurements of the swallowing function.

Background: In many cases, the manometric examination is not feasible because of the pharyngeal sinusitis or pharyngeal torsion. In addition, although previous conventional manometry was used to estimate pharyngeal swallowing, the bolus flow transmission was still not evaluated, which still depended on the videofluoscopic swallowing studies. High resolution impedance manometry could help us to measure the bolus flow according to the impedance changes. However, the comparison between two approach methods of postoperative recovery of swallowing function is still inconclusive.

Objectives: The objective of the current study was to examine the correlation between high-resolution manometric and videofluoroscopic measurements of the swallowing function.

Patients and methods: Consecutive patients who will fulfill the criteria of postoperative cervical spine surgery patients aged \>= 20 will be enrolled and the dysphagia questionnaire score (EAT-10) was higher than 3, including 3. After got the inform consent, these patients receive the swallowing function by videofluroscopy and HRIM.

Expected result: The investigator will evaluate the swallowing changes of these postoperative cervical spine patients with suspected dysphagia. The investigator expected that the highly correlation between the HRIM and VFSS.

Eligibility Criteria:
Inclusion Criteria:

* \> 20 years old
* postoperative cervical spine surgery
* EAT-10 questionnaire

Exclusion Criteria:

* pregnancy
* bleeding tendency
* heart or lung failure
Leveraging EEG for Antidepressant Prediction With Duloxetine and Bupropion

The LEAP-DB study will be conducted to validate the utility of EEG biomarkers as an aid to antidepressant treatment selection in adults with MDD.

The LEAP-DB study is an 8-week, multicenter, randomized, blinded study to evaluate the performance of EEG-based biomarkers in predicting treatment outcome. Study participants will be randomized in a 1:1 ratio to receive either duloxetine or bupropion and followed for 8 weeks.

Eligibility Criteria:
Inclusion Criteria:

* Male or female, aged 22 or older at the time of informed consent.
* Diagnosis of Major Depressive Disorder (MDD) based on the Structured Clinical Interview for DSM-5 for depression.
* Moderate or severe depression on DSM-5 depression criteria items, as assessed by a score of 10 or more on the Patient Health Questionnaire (PHQ-9)
* Has not taken either study medications (duloxetine, bupropion) in the current episode
* Has not received electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), or esketamine treatment in the current episode
* Provision of personally signed and dated written informed consent prior to any study procedures
* Agrees to, and is eligible for all biomarker assessments (EEG, neurocognitive testing, activity and sleep monitoring, genetic testing)
* Fluent in English
* Ability to complete all assessments independently
* Stated willingness to comply with all study procedures and availability for the duration of the study

Exclusion Criteria:

* Diagnosis of bipolar disorder or a psychotic disorder based on the Structured Clinical Interview for DSM-5.
* Concurrent use of antipsychotics or mood stabilizers
* Use of hypnotics, anxiolytics or opiate pain medications greater than three days per week and unable to reduce use to three or fewer days per week on an as needed basis
* Pregnant or breastfeeding
* Severe impediment to vision, hearing, comprehension, and/or hand movement that interferes with study tasks
* Active substance use that interferes with ability to consent and/or complete assessments
* Any contraindication to EEG (e.g. requiring high concentration oxygen)
* Employees/family of employees of clinic site
* Participation in another research study that began within less than 2 months prior to the first study visit
Cosmetology Students and Skin Cancer

Assess the efficacy of training cosmetology students to detect suspicious skin lesions.

The incidence of melanoma is increasing the USA. The early detection of skin cancer is associated with a significant decrease in morbidity and mortality. Hair professionals (cosmetologists and barbers) have an excellent opportunity to detect suspicious skin lesions on the scalp, neck, and face due to routinely looking at this area during customer visits. Currently in Arkansas, cosmetology schools teach students about how to recognize skin cancer on their clients. In this program, the aim was to improve the educational module for skin cancer in schools of cosmetology in Arkansas. In the proposed study, the intervention training module was designed to increase the knowledge of cosmetology schools students about skin cancer will be evaluated. It was hypothesized that this educational video will educate cosmetology students and cosmetologists about how to prevent skin cancer, how to recognize a suspicious spot or mole which may be a skin cancer, and how to talk with clients about seeing a dermatologist when a suspicious spot is found. This study was a cluster-randomized controlled trial in cosmetology schools in Arkansas. The institutional review board for human subjects at the University of Arkansas for Medical Sciences determined that this study was approved as exempt and submission was not required since it was an educational intervention to improve the quality of an educational component of the existing curriculum.

Eligibility Criteria:
Inclusion Criteria:

* For Schools: the school director agrees to participate and provide written consent
* For Students: Students were eligible at the enrolled schools if they agreed in writing to participate, filled out the baseline questionnaire, and viewed the assigned video.

Exclusion Criteria:

* The school had not recently or was not currently implementing a similar program.
Acute Effects of Three Different Types Single Leg Exercise in Copd

COPD presents not only respiratory symtoms but also vascular or muscle dysfunction. Exercise training is important for aerobic performance increasing. Generally results show exercise training with both lower limb. Increaed arterial stiffness and muscle oxygenation are observed in COPD. One leg exercise result is not enough to highlight these parameters.

Acute Effects of Three Different Types Single Leg Exercise in Copd

single bout high intensity interval training

single bout continuous exercise training single bout resistance training

Eligibility Criteria:
Inclusion Criteria:

* COPD patients that applied to physiotherapy
* cooperate to test
* no severe ortopedical and neurological disease no severe cardiovascular disease volunteer to study

Exclusion Criteria:

* have an acute exacerbation
* hypoxemia \[PaO2\] \<55 mmHg
* no cooperated to test no volunteer to study having ortophedical and neurological diesase that affecting of tests having severe cardiovascular disease